Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD3 | P35462 | 6/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | STS | P08842 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587484 | 0.93 | ESR2 (0.65) | ESR2NR1H2ESR1ABHD6DRD2 | |
| SCHEMBL30548173 | 0.93 | ESR2 (0.65) | ESR2NR1H2ESR1ABHD6DRD2 | |
| SCHEMBL1650187 | 0.93 | NR1H2 (0.63) | ESR2NR1H2ESR1ABHD6DRD2 | |
| SCHEMBL4039631 | 0.88 | ESR2 (0.56) | ESR2NR1H2ESR1NPC1RAB9A | |
| SCHEMBL6406997 | 0.88 | ESR2 (0.45) | ESR2NR1H2NPC1RAB9ADRD2 | |
| SCHEMBL29051780 | 0.86 | ESR2 (0.45) | ESR2NR1H2ESR1ABHD6DRD2 | |
| SCHEMBL30468497 | 0.86 | ESR2 (0.45) | ESR2NR1H2ESR1ABHD6DRD2 | |
| SCHEMBL29051657 | 0.85 | DRD2 (0.43) | ESR2NR1H2ESR1NPC1RAB9A | |
| SCHEMBL6188337 | 0.85 | ESR2 (0.50) | ESR2NR1H2ESR1ABHD6DRD2 | |
| SCHEMBL17462495 | 0.85 | ESR2 (0.44) | ESR2NR1H2ESR1ABHD6DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937344-B1 | PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| EP-2937344-B1 | PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | GLAXO GROUP LTD (GB) | 2017-08-23 | — | — | EP | disclosed |
| US-20160355505-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355505-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-20160355505-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9447074-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447074-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| US-9447074-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2937344-A1 | PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Glaxo Group Limited (GB) | 2015-10-28 | — | — | EP | disclosed |
| EP-2937344-A1 | PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Glaxo Group Limited (GB) | 2015-10-28 | — | — | EP | disclosed |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1119563-B1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005087746-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | disclosed |
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM PLC (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1335915-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2003-08-20 | — | — | EP | disclosed |
| US-6605607-B1 | Antihypertensives; hyperprolactinaemia related conditions; certain central nervous system disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-12 | — | — | US | disclosed |
| WO-2002040471-A9 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002040471-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-23 | — | — | WO | disclosed |
| EP-1119563-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021951-A1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | DRD3, DRD2, DRD1 | ESR2 698/4885NR1H2 204/4885ESR1 1677/4885 |
| US-20060040918-A1 | Benzo d!azepine derivatives for the treatment of neurological disorders | DRD1, DRD2, DRD3 | ESR2 1181/4885NR1H2 665/4885ESR1 832/4885 |
| US-20160355505-A1 | NOVEL COMPOUNDS | SYK, NFATC1, BTK | ESR2 3007/4885NR1H2 1423/4885ESR1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.